Clinical Trials Logo

Clinical Trial Summary

Interest in the use of probiotics as a potential treatment to reduce crying in babies with colic has increased lately. Recent studies have reported that the gut microbiota in infants with colic is characterized by lower proportions of Lactobacilli and Bifidobacteria and higher proportions of opportunistic proteobacteria (such as Escherichia coli, Enterobacter aerogenes and Klebsiella spp.) in comparison with the control babies. Therefore, based on data in the literature, it is understood that there is evidence of the effectiveness of using probiotics, either alone or in the form of a blend, to alleviate the symptoms of infantile colic.


Clinical Trial Description

Infantile colic represents a self-limiting temporary condition, which occurs in about one in five babies in the first few months of life, and is characterized by inconsolable crying and fussiness of unknown cause. Despite its benign nature, infantile colic serves as a significant source of maternal anxiety and depression, impaired family functioning, and the most common reason for seeking medical advice in this age group. Infant colic is also associated with sleep problems in babies. Parents and caregivers often seek medical attention for colic, including the use of medication, plant fiber, lactase, sucrose solution, hypoallergenic diet, and herbal tea. However, there is no single effective and safe intervention for infantile colic. Interest in the use of probiotics as a potential treatment to reduce crying in babies with colic has increased lately. Recent studies have reported that the gut microbiota in infants with colic is characterized by lower proportions of Lactobacilli and Bifidobacteria and higher proportions of opportunistic proteobacteria (such as Escherichia coli, Enterobacter aerogenes and Klebsiella spp.) in comparison with the control babies. Thus, several researchers have suggested that probiotics may be useful in treating breastfed babies with colic and reducing crying time. One study showed that administration of Lactobacillus reuteri DSM 17938 improved colic symptoms, although the effectiveness was only seen in breastfed and not formula fed infants. Another study showed that treatment with a combination of L. casei, L. rhamnosus, Streptococcus thermophilus, B. breve, L. acidophilus, B. infantiles, L. bulgaricus and fructooligosaccharides (FOS) reduced the duration of crying by almost 35 min compared to placebo. Furthermore, other authors has reported a reduced incidence of caregiver-reported colic when infants were supplemented with a combination of B. animalis subsp. lactis BB-12 and an unidentified strain of S. thermophilus, although colic was not formally diagnosed by a physician, which reduced the strength of the studies. A recent study on the same BB-12 strain overcame this deficiency by formally diagnosing colic using Rome-III criteria. However, this study showed that the response rate did not significantly improve over placebo until day 21. On the other hand, one study reported that the use of L. rhamnosus GG (ATCC53103) had no significant effect on crying in babies with colic. In another study, no significant differences were found in crying and irritability between the probiotic and placebo groups when supplemented with L. reuteri ATCC55730 or B. lactis BB-12. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05685030
Study type Interventional
Source Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
Contact
Status Recruiting
Phase Phase 2
Start date January 5, 2023
Completion date July 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT01849991 - Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic Phase 1
Completed NCT01279265 - Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic N/A
Completed NCT00177086 - Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Phase 3
Not yet recruiting NCT02577133 - Prevention of Colic With the Probiotic Lactobacillus Reuteri Phase 2/Phase 3
Recruiting NCT01715220 - Treatment of Suspected Cholelithiasis With Nitroglycerin Phase 2
Completed NCT00922727 - Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults Phase 1
Completed NCT02865564 - Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics N/A
Completed NCT01997593 - Peritoneal Ropivacaine Infiltration on Postoperative Pain in Children Affected Phase 2
Completed NCT01541046 - Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic Phase 2
Completed NCT00929292 - Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic Phase 3
Recruiting NCT05554991 - Human Milk Oligosaccharide (HMO) Supplementation in Colic Management N/A
Recruiting NCT01067027 - Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri Phase 4
Recruiting NCT04983069 - Neonatal Outcome of Children With Antenatal Colic Hyperechogenicity
Withdrawn NCT05198700 - The Effect of Probiotics on Symptoms of Infantile Colic Phase 2
Terminated NCT02586558 - Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants N/A
Completed NCT01532518 - Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance Phase 2
Completed NCT00796523 - An Intervention to Decrease Infant Crying N/A
Completed NCT05052476 - First Line Dose-efficacy Study of Bactecal® D Liquid for Infant Colic N/A
Completed NCT02242292 - Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort Phase 2
Terminated NCT00139646 - Parecoxib in Renal Colic Phase 3